Methods of treating TNF.alpha.-mediated disease using chimeric anti-TNF antibodies
US5919452A · kind A · utility
Assignees
Inventors
Key dates
| Filing date | Feb 4, 1994 |
| Grant date | Jul 6, 1999 |
| Priority date | — |
| Expiry date | Feb 4, 2014 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Treatment of tumor necrosis factor, TNF, mediated pathologies is provided by administering anti-TNF compounds, such as anti-TNF antibodies and anti-TNF peptides, which compounds are specific for tumor necrosis factor-.alpha. (TNF.alpha.) or tumor necrosis factor-.beta. (TNF.beta.) and which are useful for in vivo therapy or diagnosis of TNF.alpha.-mediated pathologies and conditions, wherein the anti-TNF compound is selected from the group consisting of at least one of an immunoglobulin variable region, a fragment of a TNF receptor and an anti-TNF peptide, such as a structural analog of a anti-TNF antibody fragment or a TNF receptor fragment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.